What's new

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Revision: 2, Status: Authorised

Apr 7, 2025 - 16:39
 0
Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Revision: 2, Status: Authorised
Read More

Tags:

Previous Article

Toyota Finally Leans Into EVs Right As The Industry Reverses Course: Report

Next Article

The D Brief: Murky hiring freeze; Trump-tariff turmoil; Cuts for CISA; GOPer sla...

Related Posts

PSUSA/00010511/202407

PSUSA/00010511/202407

Mar 19, 2025  0

Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) meetings

Executive Steering Group on Shortages and Safety of Med...

Feb 9, 2025  0

SPOR and xEVMPD Stakeholder Engagement Webinars : Substance, product, organisation and referential (SPOR) application programming interface (API) - SPOR API, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 14 October 2024, 10:00 (CEST) to 14 October 2024, 12:00 (CEST)

SPOR and xEVMPD Stakeholder Engagement Webinars : Subst...

Apr 1, 2025  0